Advus Financial Partners, LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Advus Financial Partners, LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$273K	Buy	+433	New	+$269K	0.15%	79

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Advus Financial Partners, LLC's REGN Position: Q3 2021 in Review

Advus Financial Partners, LLC opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2021: 433 shares worth $273K. The stake represents 0.15% of the portfolio and ranks #79 among its holdings.

1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Advus Financial Partners, LLC held 433 shares of Regeneron Pharmaceuticals worth $273K as of Q3 2021.
Regeneron Pharmaceuticals was a new Advus Financial Partners, LLC position in Q3 2021.
Regeneron Pharmaceuticals made up 0.15% of Advus Financial Partners, LLC's portfolio in Q3 2021, its #79 holding.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Advus Financial Partners, LLC's 13F filing for Q3 2021, filed 25 Aug 2026.